Comprehensive genomic characterization of squamous cell lung cancers
Open accessThe DOI matches its Crossref record; 45 of the 46 references it cites were found in a registry or an index, and 1 are not checked yet.
Abstract
Lung squamous cell carcinoma is a common type of lung cancer, causing approximately 400,000 deaths per year worldwide. Genomic alterations in squamous cell lung cancers have not been comprehensively characterized, and no molecularly targeted agents have been specifically developed for its treatment. As part of The Cancer Genome Atlas, here we profile 178 lung squamous cell carcinomas to provide a comprehensive landscape of genomic and epigenomic alterations. We show that the tumour type is characterized by complex genomic alterations, with a mean of 360 exonic mutations, 165 genomic rearrangements, and 323 segments of copy number alteration per tumour. We find statistically recurrent mutations in 11 genes, including mutation of TP53 in nearly all specimens. Previously unreported loss-of-function mutations are seen in the HLA-A class I major histocompatibility gene. Significantly altered pathways included NFE2L2 and KEAP1 in 34%, squamous differentiation genes in 44%, phosphatidylinositol-3-OH kinase pathway genes in 47%, and CDKN2A and RB1 in 72% of tumours. We identified a potential therapeutic target in most tumours, offering new avenues of investigation for the treatment of squamous cell lung cancers. Comprehensive analyses of 178 lung squamous cell carcinomas by The Cancer Genome Atlas project show that the tumour type is characterized by complex genomic alterations, with statistically recurrent mutations in 11 genes, including TP53 in nearly all samples; a potential therapeutic target is identified in most of the samples studied. The Cancer Genome Atlas consortium has analysed 178 lung squamous cell carcinomas, a common type of lung cancer for which comprehensive genomic analyses have not previously been available. The researchers report that this tumour type is characterized by complex genomic alterations, with recurrent mutations in 18 genes, including TP53 in nearly all samples. They also report frequent mutations in squamous differentiation genes. Collectively, these analyses identify potential therapeutic targets worthy of further investigation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Despite many additional doublings in culture, this point mutational frequency (2.16 per Mb) is on the lower end of frequencies observed across different cancer genomes22.”
From The haplotype-resolved genome and epigenome of the aneuploid HeLa cancer cell line (2013) · cites this paper as [22]
Experimental — accuracy not yet measuredIn the citing paper
“Genomic characterization of squamous cell lung cancers showed significant alterations in the Nrf2 pathway in 34% of all tumour specimens examined [175].”
From Nrf2 and Oxidative Stress: A General Overview of Mechanisms and Implications in Human Disease (2022) · cites this paper as [175]
In the citing paper
“Combined PI3K and CDK4/6 inhibition may also be of substantial interest in squamous cell NSCLC and head and neck cancer, where amplification of both CCND1 and PIK3CA are common events (117, 118), as well as in pancreatic cancer, where genetically engineered mouse models have suggested the importance of the PI3K pathway downstream from activated KRAS (119).”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [118]
In the citing paper
“The TP53 mutation rate exceeds 70% in certain subtypes of cancers, including squamous esophageal cancer, small-cell lung cancer, squamous cell lung cancer, and complex karyotype acute myeloid leukemia (AML), and is lower in partial tumors such as lymphoma, melanoma, and overall AML.8–11”
From p53: from understanding its structure to advances in therapeutic targeting (2026) · cites this paper as [10]
In the citing paper
“The TP53 mutation rate exceeds 70% in certain subtypes of cancers, including squamous esophageal cancer, small-cell lung cancer, squamous cell lung cancer, and complex karyotype acute myeloid leukemia (AML), and is lower in partial tumors such as lymphoma, melanoma, and overall AML.8–11”
From p53: from understanding its structure to advances in therapeutic targeting (2026) · cites this paper as [10]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Self-citationIntegrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,925
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
Soda, M., Choi, Y. L., Enomoto, M., Takada, S., Yamashita, Y., Ishikawa, S., Fujiwara, S.-I., Watanabe, H., Kurashina, K., Hatanaka, H., et al. (2007) · Nature · doi:10.1038/nature05945 · Cited by 5,439 · cited 1×
“2); (2) confirmation of the altered allele in RNA sequencing; and (3) the mutation assessor score(40).”
BackgroundPao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338
The landscape of somatic copy-number alteration across human cancers
Beroukhim, R., Mermel, C. H., Porter, D., Wei, G., Raychaudhuri, S., Donovan, J., Barretina, J., Boehm, J. S., Dobson, J., Urashima, M., et al. (2010) · Nature · doi:10.1038/nature08822 · Cited by 4,017
Self-citationMermel, C. H., Schumacher, S. E., Hill, B., Meyerson, M. L., Beroukhim, R., & Getz, G. (2011) · Genome Biology · doi:10.1186/gb-2011-12-4-r41 · Cited by 3,550
Brahmer, J. R., Drake, C. G., Wollner, I., Powderly, J. D., Picus, J., Sharfman, W. H., Stankevich, E., Pons, A., Salay, T. M., McMiller, T. L., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.7609 · Cited by 2,961
Cited by
Items 501–600 of 1,021
Next-generation sequencing technologies: breaking the sound barrier of human genetics
Bahassi, E. M., & Stambrook, P. J. (2014) · Mutagenesis · doi:10.1093/mutage/geu031 · Cited by 163
Perspectives of the Nrf-2 signaling pathway in cancer progression and therapy
Basak, P., Sadhukhan, P., Sarkar, P., & Sil, P. C. (2017) · Toxicology Reports · doi:10.1016/j.toxrep.2017.06.002 · Cited by 147
Genomic insights into cancer-associated aberrant CpG island hypermethylation
Sproul, D., & Meehan, R. R. (2013) · Briefings in Functional Genomics · doi:10.1093/bfgp/els063 · Cited by 162
KMT2D maintains neoplastic cell proliferation and global histone H3 lysine 4 monomethylation
Guo, C., Chen, L. H., Huang, Y., Chang, C., Wang, P., Pirozzi, C. J., Qin, X., Bao, X., Greer, P. K., McLendon, R. E., et al. (2013) · Oncotarget · doi:10.18632/oncotarget.1555 · Cited by 146
Aredo, J. V., Padda, S. K., Kunder, C. A., Han, S. S., Neal, J. W., Shrager, J. B., & Wakelee, H. A. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.05.015 · Cited by 132
Helsten, T. L., Schwaederle, M. C., & Kurzrock, R. (2015) · Cancer and Metastasis Reviews · doi:10.1007/s10555-015-9579-8 · Cited by 135
Survivin and YM155: How faithful is the liaison?
Rauch, A., Hennig, D., Schäfer, C., Wirth, M., Marx, C., Heinzel, T., Schneider, G., & Krämer, O. H. (2014) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2014.01.003 · Cited by 145
IAPP-driven metabolic reprogramming induces regression of p53-deficient tumours in vivo
Venkatanarayan, A., Raulji, P., Norton, W., Chakravarti, D., Coarfa, C., Su, X., Sandur, S. K., Ramirez, M. S., Lee, J., Kingsley, C. V., et al. (2015) · Nature · doi:10.1038/nature13910 · Cited by 130
Creighton, C. J., Gibbons, D. L., & Kurie, J. M. (2013) · Cancer Management and Research · doi:10.2147/cmar.s35171 · Cited by 150
Association of tumor TROP2 expression with prognosis varies among lung cancer subtypes
Inamura, K., Yokouchi, Y., Kobayashi, M., Ninomiya, H., Sakakibara, R., Subat, S., Nagano, H., Nomura, K., Okumura, S., Shibutani, T., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.15647 · Cited by 146
Karp, D. D., Lee, S. J., Keller, S. M., Wright, G. S., Aisner, S., Belinsky, S. A., Johnson, D. H., Johnston, M. R., Goodman, G., Clamon, G., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.2173 · Cited by 130
The role of wild type RAS isoforms in cancer
Zhou, B., Der, C. J., & Cox, A. D. (2016) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2016.07.012 · Cited by 130
Mutation of cancer driver MLL2 results in transcription stress and genome instability
Kantidakis, T., Saponaro, M., Mitter, R., Horswell, S., Kranz, A., Boeing, S., Aygün, O., Kelly, G. P., Matthews, N., Stewart, A., et al. (2016) · Genes & Development · doi:10.1101/gad.275453.115 · Cited by 130
Conditional Selection of Genomic Alterations Dictates Cancer Evolution and Oncogenic Dependencies
Mina, M., Raynaud, F., Tavernari, D., Battistello, E., Sungalee, S., Saghafinia, S., Laessle, T., Sanchez-Vega, F., Schultz, N., Oricchio, E., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.06.010 · Cited by 129
Kawaguchi, T., Koh, Y., Ando, M., Ito, N., Takeo, S., Adachi, H., Tagawa, T., Kakegawa, S., Yamashita, M., Kataoka, K., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.2322 · Cited by 140
Insertions and Deletions Target Lineage-Defining Genes in Human Cancers
Imielinski, M., Guo, G., & Meyerson, M. (2017) · Cell · doi:10.1016/j.cell.2016.12.025 · Cited by 129
Activation of p62/SQSTM1–Keap1–Nuclear Factor Erythroid 2-Related Factor 2 Pathway in Cancer
Ichimura, Y., & Komatsu, M. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00210 · Cited by 141
Hanley, C. J., Waise, S., Ellis, M. J., Lopez, M. A., Pun, W. Y., Taylor, J., Parker, R., Kimbley, L., Chee, S., Shaw, E. C., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-35832-6 · Cited by 155
Govindan, R., Mandrekar, S. J., Gerber, D. E., Oxnard, G. R., Dahlberg, S. E., Chaft, J. E., Malik, S. M., Mooney, M., Abrams, J. S., Janne, P. A., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0354 · Cited by 130
Zhang, J., Späth, S. S., Marjani, S. L., Zhang, W., & Pan, X. (2018) · Precision Clinical Medicine · doi:10.1093/pcmedi/pby007 · Cited by 154
Cho, R. J., Alexandrov, L. B., den Breems, N. Y., Atanasova, V. S., Farshchian, M., Purdom, E. A., Nguyen, T., Coarfa, C., Rajapakshe, K., di Prisco, M., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aas9668 · Cited by 139
Effect Sizes of Somatic Mutations in Cancer
Cannataro, V. L., Gaffney, S. G., & Townsend, J. P. (2018) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djy168 · Cited by 135
A clonal expression biomarker associates with lung cancer mortality
TRACERx Consortium, Biswas, D., Birkbak, N. J., Rosenthal, R., Hiley, C. T., Lim, E. L., Papp, K., Boeing, S., Krzystanek, M., Djureinovic, D., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0595-z · Cited by 127
Lkb1 inactivation drives lung cancer lineage switching governed by Polycomb Repressive Complex 2
Zhang, H., Fillmore Brainson, C., Koyama, S., Redig, A. J., Chen, T., Li, S., Gupta, M., Garcia-de-Alba, C., Paschini, M., Herter-Sprie, G. S., et al. (2017) · Nature Communications · doi:10.1038/ncomms14922 · Cited by 127
Self-citationZhang, X., Choi, P. S., Francis, J. M., Gao, G. F., Campbell, J. D., Ramachandran, A., Mitsuishi, Y., Ha, G., Shih, J., Vazquez, F., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0532 · Cited by 126
Biopsies: next-generation biospecimens for tailoring therapy
Basik, M., Aguilar‐Mahecha, A., Rousseau, C., Diaz, Z., Tejpar, S., Spatz, A., Greenwood, C. M. T., & Batist, G. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.101 · Cited by 126
Integrative Radiogenomic Profiling of Squamous Cell Lung Cancer
Abazeed, M. E., Adams, D. J., Hurov, K. E., Tamayo, P., Creighton, C. J., Sonkin, D., Giacomelli, A. O., Du, C., Fries, D. F., Wong, K.-K., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1616 · Cited by 124
Molecular Pathology of Primary Non-small Cell Lung Cancer
Suster, D. I., & Mino-Kenudson, M. A. (2020) · Archives of Medical Research · doi:10.1016/j.arcmed.2020.08.004 · Cited by 144
Redman, M. W., Papadimitrakopoulou, V. A., Minichiello, K., Hirsch, F. R., Mack, P. C., Schwartz, L. H., Vokes, E. E., Ramalingam, S. S., Leighl, N. B., Bradley, J. D., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30475-7 · Cited by 129
The mutational landscape of chromatin regulatory factors across 4,623 tumor samples
Gonzalez-Perez, A., Jene-Sanz, A., & Lopez-Bigas, N. (2013) · Genome Biology · doi:10.1186/gb-2013-14-9-r106 · Cited by 125
Clonal evolution patterns in acute myeloid leukemia with NPM1 mutation
Cocciardi, S., Dolnik, A., Kapp‐Schwoerer, S., Rücker, F. G., Lux, S., Blätte, T. J., Skambraks, S., Krönke, J., Heidel, F. H., Schnoeder, T. M., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09745-2 · Cited by 139
Jeong, Y., Hellyer, J. A., Stehr, H., Hoang, N. T., Niu, X., Das, M., Padda, S. K., Ramchandran, K., Neal, J. W., Wakelee, H., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1237 · Cited by 124
Hensing, T. A., Chawla, A., Batra, R., & Salgia, R. (2013) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-8778-4_5 · Cited by 142
Shepherd, F. A., Lacas, B., Le Teuff, G., Hainaut, P., Jänne, P. A., Pignon, J.-P., Le Chevalier, T., Seymour, L., Douillard, J.-Y., Graziano, S., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.2893 · Cited by 124
Next generation sequencing in cancer research and clinical application
Shyr, D., & Liu, Q. (2013) · Biological Procedures Online · doi:10.1186/1480-9222-15-4 · Cited by 153
Network-based machine learning and graph theory algorithms for precision oncology
Zhang, W., Chien, J., Yong, J., & Kuang, R. (2017) · npj Precision Oncology · doi:10.1038/s41698-017-0029-7 · Cited by 124
The genomic landscape of Epstein-Barr virus-associated pulmonary lymphoepithelioma-like carcinoma
Hong, S., Liu, D., Luo, S., Fang, W., Zhan, J., Fu, S., Zhang, Y., Wu, X., Zhou, H., Chen, X., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10902-w · Cited by 126
Form and function of the Golgi apparatus: scaffolds, cytoskeleton and signalling
Gosavi, P., Makhoul, C., & Gleeson, P. A. (2019) · FEBS Letters · doi:10.1002/1873-3468.13567 · Cited by 131
A novel circular RNA, circXPO1, promotes lung adenocarcinoma progression by interacting with IGF2BP1
Huang, Q., Guo, H., Wang, S., Ma, Y., Chen, H., Li, H., Li, J., Li, X., Yang, F., Qiu, M., et al. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-03237-8 · Cited by 136
Yu, K.-H., Wang, F., Berry, G. J., Ré, C., Altman, R. B., Snyder, M., & Kohane, I. S. (2020) · Journal of the American Medical Informatics Association · doi:10.1093/jamia/ocz230 · Cited by 121
Zhao, Y., Pan, Z., Namburi, S., Pattison, A., Posner, A., Balachander, S., Paisie, C. A., Reddi, H. V., Rueter, J., Gill, A. J., et al. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.103030 · Cited by 122
Li, L.-Y., Yang, Q., Jiang, Y.-Y., Yang, W., Jiang, Y. Y., Li, X., Hazawa, M., Zhou, B. O., Huang, G.-W., Xu, X., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24656-x · Cited by 144
Sánchez-Ortega, M., Carrera, A. C., & Garrido, A. (2021) · Cells · doi:10.3390/cells10081879 · Cited by 140
Conumee 2.0: enhanced copy-number variation analysis from DNA methylation arrays for humans and mice
Daenekas, B., Pérez, E., Boniolo, F., Ştefan, S., Benfatto, S., Sill, M., Sturm, D., Jones, D., Capper, D., Zapatka, M., et al. (2024) · Bioinformatics · doi:10.1093/bioinformatics/btae029 · Cited by 161
Targeting the peripheral neural-tumour microenvironment for cancer therapy
Yaniv, D., Mattson, B. J., Talbot, S., Gleber‐Netto, F. O., & Amit, M. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-01017-z · Cited by 152
The impact of the Cancer Genome Atlas on lung cancer
Chang, J. T.-H., Lee, Y. M., & Huang, R. S. (2015) · Translational research · doi:10.1016/j.trsl.2015.08.001 · Cited by 141
CanDrA: Cancer-Specific Driver Missense Mutation Annotation with Optimized Features
Mao, Y., Chen, H., Liang, H., Meric-Bernstam, F., Mills, G. B., & Chen, K. (2013) · PLoS ONE · doi:10.1371/journal.pone.0077945 · Cited by 122
Nakanishi, Y., Akiyama, N., Tsukaguchi, T., Fujii, T., Sakata, K., Sase, H., Isobe, T., Morikami, K., Shindoh, H., Mio, T., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0248 · Cited by 127
Xu, J., Wu, P., Chen, Y., Meng, Q., Dawood, H., & Dawood, H. (2019) · BMC Bioinformatics · doi:10.1186/s12859-019-3116-7 · Cited by 121
Caldéraro, J., Masliah‐Planchon, J., Richer, W., Maillot, L., Maillé, P., Mansuy, L., Bastien, C., TAILLE, A. D. L., Boussion, H., Charpy, C., et al. (2015) · European Urology · doi:10.1016/j.eururo.2015.09.027 · Cited by 121
Buettner, R., Wolf, J., & Thomas, R. K. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.9867 · Cited by 121
Proteogenomic landscape of squamous cell lung cancer
Stewart, P. A., Welsh, E. A., Slebos, R. J. C., Fang, B., Izumi, V., Chambers, M., Zhang, G., Cen, L., Pettersson, F., Zhang, Y., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11452-x · Cited by 120
CDKN2A Alterations and Response to Immunotherapy in Solid Tumors
Adib, E., Nassar, A. H., Akl, E. W., Alaiwi, S. A., Nuzzo, P. V., Mouhieddine, T. H., Sonpavde, G., Haddad, R. I., Mouw, K. W., Giannakis, M., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0575 · Cited by 132
Evolution of metastasis revealed by mutational landscapes of chemically induced skin cancers
McCreery, M. Q., Halliwill, K. D., Chin, D., Delrosario, R., Hirst, G., Vuong, P., Jen, K.-Y., Hewinson, J., Adams, D. J., & Balmain, A. (2015) · Nature Medicine · doi:10.1038/nm.3979 · Cited by 120
The bromodomain protein BRD4 regulates the KEAP1/NRF2-dependent oxidative stress response
Hussong, M., Börno, S. T., Kerick, M., Wunderlich, A., Franz, A., Sültmann, H., Timmermann, B., Lehrach, H., Hirsch-Kauffmann, M., & Schweiger, M. R. (2014) · Cell Death & Disease · doi:10.1038/cddis.2014.157 · Cited by 120
MUC1-C integrates PD-L1 induction with repression of immune effectors in non-small-cell lung cancer
Bouillez, A., Rajabi, H., Jin, C., Samur, M., Tagde, A., Alam, M., Hiraki, M., Maeda, T., Hu, X., Adeegbe, D., et al. (2017) · Oncogene · doi:10.1038/onc.2017.47 · Cited by 120
Identification of a functional antioxidant response element at the HIF1A locus
Lacher, S. E., Levings, D. C., Freeman, S., & Slattery, M. (2018) · Redox Biology · doi:10.1016/j.redox.2018.08.014 · Cited by 119
Genomic Profiling of Lung Adenocarcinoma in Never-Smokers
Devarakonda, S., Li, Y., Rodrigues, F. M., Sankararaman, S., Kadara, H. N., Goparaju, C., Lanc, I., Pepin, K., Waqar, S. N., Morgensztern, D., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.01691 · Cited by 146
Transforming Epidemiology for 21st Century Medicine and Public Health
Khoury, M. J., Lam, T. K., Ioannidis, J. P. A., Hartge, P., Spitz, M. R., Buring, J. E., Chanock, S. J., Croyle, R. T., Goddard, K. A., Ginsburg, G. S., et al. (2013) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-13-0146 · Cited by 119
Liu, L., De, S., & Michor, F. (2013) · Nature Communications · doi:10.1038/ncomms2502 · Cited by 119
Pemov, A., Li, H., Patidar, R., Hansen, N. F., Sindiri, S., Hartley, S. W., Wei, J. S., ELKAHLOUN, A. G., Chandrasekharappa, S. C., Program, N. C. S., et al. (2017) · Oncogene · doi:10.1038/onc.2016.464 · Cited by 134
Molecular Mechanisms and Targeted Therapies Including Immunotherapy for Non-Small Cell Lung Cancer
Nagano, T., TACHIHARA, M. Y., & Nishimura, Y. (2018) · Current Cancer Drug Targets · doi:10.2174/1568009619666181210114559 · Cited by 129
Mottini, C., Napolitano, F., Li, Z., Gao, X., & Cardone, L. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.09.023 · Cited by 118
Identification of recurrent FGFR3 fusion genes in lung cancer through kinome‐centred RNA sequencing
Majewski, I. J., Mittempergher, L., Davidson, N., Bosma, A. R., Willems, S. M., Horlings, H. M., de Rink, I., Greger, L., Hooijer, G. K. J., Peters, D. D. G. C., et al. (2013) · The Journal of Pathology · doi:10.1002/path.4209 · Cited by 132
Pan-Cancer Analysis of Mutation Hotspots in Protein Domains
Miller, M. L., Reznik, E., Gauthier, N. P., Aksoy, B. A., Korkut, A., Gao, J., Ciriello, G., Schultz, N., & Sander, C. (2015) · Cell Systems · doi:10.1016/j.cels.2015.08.014 · Cited by 118
Vartanian, S., Ma, T. P., Lee, J., Haverty, P. M., Kirkpatrick, D. S., Yu, K., & Stokoe, D. (2016) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m115.055509 · Cited by 113
Kohsaka, S., Petronczki, M. P., Solca, F., & Maemondo, M. (2018) · Future Oncology · doi:10.2217/fon-2018-0736 · Cited by 131
The role of natural products in revealing NRF2 function
Zhang, D. D., & Chapman, E. (2020) · Natural Product Reports · doi:10.1039/c9np00061e · Cited by 124
Malik, V., Kalakoti, Y., & Sundar, D. (2021) · BMC Genomics · doi:10.1186/s12864-021-07524-2 · Cited by 138
Saunus, J. M., Quinn, M. C. J., Patch, A., Pearson, J. V., Bailey, P. J., Nones, K., Reed, A. E. M., Miller, D. K., Wilson, P. J., Al‐Ejeh, F., et al. (2015) · The Journal of Pathology · doi:10.1002/path.4583 · Cited by 130
Beck, J. T., Ismail, A., & Tolomeo, C. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2014.06.006 · Cited by 124
Mediator kinase module and human tumorigenesis
Clark, A. D., Oldenbroek, M., & Boyer, T. (2015) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.3109/10409238.2015.1064854 · Cited by 135
Systematic discovery of complex insertions and deletions in human cancers
Ye, K., Wang, J., Jayasinghe, R., Lameijer, E.-W., McMichael, J. F., Ning, J., McLellan, M. D., Xie, M., Cao, S., Yellapantula, V., et al. (2016) · Nature Medicine · doi:10.1038/nm.4002 · Cited by 117
Tagal, V., Wei, S., Zhang, W., Brekken, R. A., Posner, B. A., Peyton, M., Girard, L., Hwang, T., Wheeler, D. A., Minna, J. D., et al. (2017) · Nature Communications · doi:10.1038/ncomms14098 · Cited by 129
DACH1 antagonizes CXCL8 to repress tumorigenesis of lung adenocarcinoma and improve prognosis
Liu, Q., Li, A., Yu, S., Qin, S., Han, N., Pestell, R. G., Han, X., & Wu, K. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0597-1 · Cited by 116
Metabolic Regulation of Redox Balance in Cancer
Purohit, V., Simeone, D. M., & Lyssiotis, C. A. (2019) · Cancers · doi:10.3390/cancers11070955 · Cited by 117
MEK and PI3K inhibition in solid tumors: rationale and evidence to date
Jokinen, E., & Koivunen, J. P. (2015) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834015571111 · Cited by 116
Augert, A., Zhang, Q., Bates, B., Cui, M., Wang, X., Wildey, G., Dowlati, A., & MacPherson, D. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.12.011 · Cited by 115
TGFβ pathway inhibition in the treatment of non-small cell lung cancer
Eser, P. Ö., & Janne, P. A. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.11.004 · Cited by 122
Wang, C., Yin, R., Dai, J., Gu, Y., Cui, S., Ma, H., Zhang, Z., Huang, J., Qin, N., Jiang, T., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04492-2 · Cited by 116
A Human Adult Stem Cell Signature Marks Aggressive Variants across Epithelial Cancers
Smith, B. A., Balanis, N. G., Nanjundiah, A., Sheu, K. M., Tsai, B. L., Zhang, Q., Park, J. W., Thompson, M. J., Huang, J., Witte, O. N., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.08.062 · Cited by 141
Targeted Therapies in Non-Small Cell Lung Cancer—Beyond EGFR and ALK
Rothschild, S. (2015) · Cancers · doi:10.3390/cancers7020816 · Cited by 115
Li, L., Wei, Y., To, C., Zhu, C., Tong, J., Pham, N., Taylor, P. P., Ignatchenko, V., Ignatchenko, A., Zhang, W., et al. (2014) · Nature Communications · doi:10.1038/ncomms6469 · Cited by 130
Tipifarnib as a Precision Therapy for HRAS -Mutant Head and Neck Squamous Cell Carcinomas
Gilardi, M., Wang, Z., Proietto, M., Chillà, A., Calleja-Valera, J. L., Goto, Y., Vanoni, M., Janes, M. R., Mikulski, Z., Gualberto, A., et al. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0958 · Cited by 132
Lehtiö, J., Arslan, T., Siavelis, I., Pan, Y., Socciarelli, F., Berkovska, O., Umer, H. M., Mermelekas, G., Pirmoradian, M., Jönsson, M., et al. (2021) · Nature Cancer · doi:10.1038/s43018-021-00259-9 · Cited by 131
Lee, H., Palm, J., Grimes, S. M., & Ji, H. P. (2015) · Genome Medicine · doi:10.1186/s13073-015-0226-3 · Cited by 115
Pancancer analysis of DNA methylation-driven genes using MethylMix
Gevaert, O., Tibshirani, R. J., & Plevritis, S. K. (2015) · Genome biology · doi:10.1186/s13059-014-0579-8 · Cited by 123
Choi, E.-J., Jung, B.-J., Lee, S.-H., Yoo, H.-S., Shin, E.-A., Ko, H., Chang, S., Kim, S.-Y., & Jeon, S.-M. (2017) · Oncogene · doi:10.1038/onc.2017.153 · Cited by 119
Pan-cancer analysis of whole genomes
Campbell, P. J., Getz, G., Stuart, J. M., Korbel, J. O., & Stein, L. D. (2017) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/162784 · Cited by 114
Omberg, L., Ellrott, K., Yuan, Y., Kandoth, C., Wong, C., Kellen, M. R., Friend, S. H., Stuart, J., Liang, H., & Margolin, A. A. (2013) · Nature Genetics · doi:10.1038/ng.2761 · Cited by 112
The Pivotal Role of IKKα in the Development of Spontaneous Lung Squamous Cell Carcinomas
Xiao, Z., Jiang, Q., Willette‐Brown, J., Xi, S., Zhu, F., Burkett, S. S., Back, T. C., Song, N., Datla, M., Sun, Z., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.03.009 · Cited by 119
Karlsson, A., Jönsson, M., Lauss, M., Brunnström, H., Jönsson, P., Borg, Å., Jönsson, G. B., Ringnér, M., Planck, M., & Staaf, J. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1087 · Cited by 120
Do, H., Wong, S. Q., Li, J., & Dobrovic, A. (2013) · Clinical Chemistry · doi:10.1373/clinchem.2012.202390 · Cited by 128
Zhou, W., Wei, W., & Sun, Y. (2013) · Cell Research · doi:10.1038/cr.2013.44 · Cited by 112
p62/SQSTM 1—Dr. Jekyll and Mr. Hyde that prevents oxidative stress but promotes liver cancer
Taniguchi, K., Yamachika, S., He, F., & Karin, M. (2016) · FEBS Letters · doi:10.1002/1873-3468.12301 · Cited by 112
Zapata, L., Pich, O., Serrano, L., Kondrashov, F. A., Ossowski, S., & Schaefer, M. H. (2018) · Genome biology · doi:10.1186/s13059-018-1434-0 · Cited by 135
Solid Tumors Challenges and New Insights of CAR T Cell Engineering
Tahmasebi, S., Elahi, R., & Esmaeilzadeh, A. (2019) · Stem Cell Reviews and Reports · doi:10.1007/s12015-019-09901-7 · Cited by 144
EPISCORE: cell type deconvolution of bulk tissue DNA methylomes from single-cell RNA-Seq data
Teschendorff, A. E., Zhu, T., Breeze, C. E., & Beck, S. (2020) · Genome Biology · doi:10.1186/s13059-020-02126-9 · Cited by 112
Choi, M., Kadara, H. N., Zhang, J., Parra, E. R., Rodriguez‐Canales, J., Gaffney, S. G., Zhao, Z.-M., Behrens, C., Fujimoto, J., Chow, C.-W. B., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw437 · Cited by 111
COHCAP: an integrative genomic pipeline for single-nucleotide resolution DNA methylation analysis
Warden, C., Lee, H., Tompkins, J. D., Li, X., Wang, C., Riggs, A. D., Yu, H., Jove, R., & Yuan, Y. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt242 · Cited by 132
Metadata
- Authors
- The Cancer Genome Atlas Research Network
- Venue
- Nature
- Published
- 2012-09-09
- Volume
- 489
- Issue
- 7417
- Pages
- 519-525
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC3466113
- OpenAlex
- W2275877493
- Cited by
- 3,994
- References
- 45
- Citations by year
- 2026: 153 · 2025: 181 · 2024: 189 · 2023: 204 · 2022: 262 · 2021: 296 · 2020: 360 · 2019: 286 · 2018: 329 · 2017: 353 · 2016: 346 · 2015: 371 · 2014: 335 · 2013: 300 · 2012: 24
- FWCI
- 263.50
- Type
- journal article
- Language
- en
- Update notices
- erratum (2012-11-07)
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-sa
- creativecommons.org/licenses/by-nc-sa/3.0/ (tdm)
- creativecommons.org/licenses/by-nc-sa/3.0/ (vor)
- Locations
- Nature (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Kölner Universitäts PublikationsServer (Universität zu Köln) (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by-nc-sa)
- DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by-nc-sa)
- Max Planck Institute for Plasma Physics (submittedVersion)
- eSpace (Curtin University) (submittedVersion, cc-by-nc-sa)
- MPG.PuRe (Max Planck Society) (submittedVersion)
- Scholarworks@UNIST (Ulsan National Institute of Science and Technology) (submittedVersion)
- Funders
- National Institutes of Health (5r01ca149569-05)
- BC Cancer Agency
- National Human Genome Research Institute (U54HG003067, HG003067, U54HG003079, HG003079, HG003273, U54HG003273, R01HG006272)
- National Cancer Institute (R01CA094143, U24CA126554, U24CA143882, R01-CA149569, U24CA143843, U24CA143840, U24CA126546, CA143883, U24CA143858, K08CA137153, U24CA126543, U24CA144025, U24CA126563, U24CA143866, U24CA143883, CA143840, U24CA143845, U24CA126544, R00CA149182, U24CA143867, U24CA143848, U24CA143799, U24CA126551, U24CA143835, U24CA126561, T32CA009172, P30CA016672, P30CA016086)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Keywords
- lung squamous cell carcinoma, genetic alterations, epigenomic alterations, TP53 mutation, copy number alterations, genome rearrangement, Nrf2, Keap1, PI3K signaling, CDKN2A, RB1, therapeutic target, TCGA
- MeSH terms
- Adenocarcinoma of Lung, Adenocarcinoma, Carcinoma, Squamous Cell, DNA Mutational Analysis, Humans, Lung Neoplasms, Mutation, Signal Transduction, Genome, Human, Gene Expression Regulation, Neoplastic, Genes, p53, Gene Deletion, Phosphatidylinositol 3-Kinases, Genes, p16, Gene Expression Profiling, Genomics, Molecular Targeted Therapy, Mutation Rate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.